NEW ORLEANS — At 24 weeks, more patients in the intravitreal aflibercept arm of the VIBRANT study gained at least 15 letters of visual acuity than patients receiving laser to treat macular edema secondary to branch retinal vein occlusion, according to a presenter here.
More than 90% of patients in both groups completed the primary outcome visit at week 24, with 53% of patients in the Eylea (aflibercept, Regeneron) group and 27% of patients in the laser group gaining 15 letters or more of visual acuity, W. Lloyd Clark, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
W. Lloyd Clark
The ongoing VIBRANT study is a multicenter double-masked trial of 183 patients with center-involved macular edema randomized to receive either monthly aflibercept or laser at baseline. All eyes were treatment naïve.
“In patients with vision loss secondary to retinal vein occlusion, monthly intravitreal aflibercept injections resulted in superior gain in visual acuity and significant reduction in macular edema compared to laser,” Clark said.
“Differences between treatment groups were statistically significant. Intravitreal aflibercept is well tolerated. The most common ocular adverse events were those associated with intravitreal injection procedure,” he said.
Disclosure: Clark is a consultant to and receives research funding from Genentech/Roche, Regeneron and Santen. He receives research funding from Allergan.